How much revenue did Insulet generate this year?
Insulet has achieved a revenue of 2.48 B USD this year.
Insulet Revenue 2025
Insulet Revenue
2.48 B USD
Ticker
PODD
ISIN
US45784P1012
WKN
A0MQX8
In 2025, Insulet's sales reached 2.48 B USD, a 18.07% difference from the 2.1 B USD sales recorded in the previous year.
The Insulet Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 4.06 | 28,59 |
| 2028e | 3.67 | 31,57 |
| 2027e | 3.29 | 35,29 |
| 2026e | 2.9 | 39,96 |
| 2025e | 2.48 | 46,85 |
| 2024e | 2.1 | 55,31 |
| 2023 | 1.7 | 68,35 |
| 2022 | 1.31 | 61,72 |
| 2021 | 1.1 | 68,45 |
| 2020 | 0.9 | 64,39 |
| 2019 | 0.74 | 65,06 |
| 2018 | 0.56 | 65,66 |
| 2017 | 0.46 | 59,77 |
| 2016 | 0.37 | 57,52 |
| 2015 | 0.26 | 50,51 |
| 2014 | 0.23 | 54,95 |
| 2013 | 0.25 | 45,49 |
| 2012 | 0.21 | 43,66 |
| 2011 | 0.15 | 43,80 |
| 2010 | 0.1 | 45,05 |
| 2009 | 0.07 | 27,73 |
| 2008 | 0.04 | -12,74 |
| 2007 | 0.01 | -92,54 |
| 2006 | 0 | -324,32 |
| 2005 | 0 | -1500,00 |
| 2004 | - | - |
Insulet Revenue, EBIT, Net Income US45784P1012 · A0MQX8
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Insulet, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Insulet from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Insulet’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Insulet. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Insulet’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Insulet’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Insulet’s growth potential.
Insulet Revenue, EBIT and net profit per share
| Date | Insulet Revenue | Insulet EBIT | Insulet Net Income |
|---|---|---|---|
| 2029e | 4.06 B undefined | 785.5 M undefined | 622.42 M undefined |
| 2028e | 3.67 B undefined | 694.57 M undefined | 453.58 M undefined |
| 2027e | 3.29 B undefined | 583.62 M undefined | 410.3 M undefined |
| 2026e | 2.9 B undefined | 478.22 M undefined | 346.2 M undefined |
| 2025e | 2.48 B undefined | 381.31 M undefined | 277.79 M undefined |
| 2024e | 2.1 B undefined | 303.21 M undefined | 236.59 M undefined |
| 2023 | 1.7 B undefined | 220 M undefined | 206.3 M undefined |
| 2022 | 1.31 B undefined | 37.6 M undefined | 4.6 M undefined |
| 2021 | 1.1 B undefined | 126 M undefined | 16.8 M undefined |
| 2020 | 904.4 M undefined | 51.5 M undefined | 6.8 M undefined |
| 2019 | 738.2 M undefined | 50 M undefined | 11.6 M undefined |
| 2018 | 563.8 M undefined | 40 M undefined | 3.3 M undefined |
| 2017 | 463.8 M undefined | -7.4 M undefined | -26.8 M undefined |
| 2016 | 367 M undefined | -10.7 M undefined | -28.9 M undefined |
| 2015 | 263.9 M undefined | -48.7 M undefined | -73.5 M undefined |
| 2014 | 231.3 M undefined | -8.9 M undefined | -51.5 M undefined |
| 2013 | 247.1 M undefined | -29.2 M undefined | -45 M undefined |
| 2012 | 211.4 M undefined | -36 M undefined | -51.9 M undefined |
| 2011 | 152.3 M undefined | -40.8 M undefined | -45.8 M undefined |
| 2010 | 97 M undefined | -34.2 M undefined | -61.2 M undefined |
| 2009 | 66 M undefined | -59.4 M undefined | -72.3 M undefined |
| 2008 | 36.1 M undefined | -81.1 M undefined | -94.8 M undefined |
| 2007 | 13.4 M undefined | -52.8 M undefined | -53.5 M undefined |
| 2006 | 3.7 M undefined | -34.6 M undefined | -36.2 M undefined |
| 2005 | 100,000 undefined | -21.5 M undefined | -21.6 M undefined |
| 2004 | 0 undefined | -14.2 M undefined | -13.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 USD | -14.2 M USD | -13.9 M USD |
| 2005 | 100,000 USD | -21.5 M USD | -21.6 M USD |
| 2006 | 3.7 M USD | -34.6 M USD | -36.2 M USD |
| 2007 | 13.4 M USD | -52.8 M USD | -53.5 M USD |
| 2008 | 36.1 M USD | -81.1 M USD | -94.8 M USD |
| 2009 | 66 M USD | -59.4 M USD | -72.3 M USD |
| 2010 | 97 M USD | -34.2 M USD | -61.2 M USD |
| 2011 | 152.3 M USD | -40.8 M USD | -45.8 M USD |
| 2012 | 211.4 M USD | -36 M USD | -51.9 M USD |
| 2013 | 247.1 M USD | -29.2 M USD | -45 M USD |
| 2014 | 231.3 M USD | -8.9 M USD | -51.5 M USD |
| 2015 | 263.9 M USD | -48.7 M USD | -73.5 M USD |
| 2016 | 367 M USD | -10.7 M USD | -28.9 M USD |
| 2017 | 463.8 M USD | -7.4 M USD | -26.8 M USD |
| 2018 | 563.8 M USD | 40 M USD | 3.3 M USD |
| 2019 | 738.2 M USD | 50 M USD | 11.6 M USD |
| 2020 | 904.4 M USD | 51.5 M USD | 6.8 M USD |
| 2021 | 1.1 B USD | 126 M USD | 16.8 M USD |
| 2022 | 1.31 B USD | 37.6 M USD | 4.6 M USD |
| 2023 | 1.7 B USD | 220 M USD | 206.3 M USD |
| 2024e | 2.1 B USD | 303.21 M USD | 236.59 M USD |
| 2025e | 2.48 B USD | 381.31 M USD | 277.79 M USD |
| 2026e | 2.9 B USD | 478.22 M USD | 346.2 M USD |
| 2027e | 3.29 B USD | 583.62 M USD | 410.3 M USD |
| 2028e | 3.67 B USD | 694.57 M USD | 453.58 M USD |
| 2029e | 4.06 B USD | 785.5 M USD | 622.42 M USD |
Insulet stock margins US45784P1012 · A0MQX8
The Insulet margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Insulet. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Insulet.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Insulet's sales revenue. A higher gross margin percentage indicates that the Insulet retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Insulet's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Insulet's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Insulet's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Insulet. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Insulet's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Insulet Margin History
| Insulet Gross margin | Insulet Profit margin | Insulet EBIT margin | Insulet Profit margin |
|---|---|---|---|
| 2029e | 68.35 % | 19.36 % | 15.34 % |
| 2028e | 68.35 % | 18.91 % | 12.35 % |
| 2027e | 68.35 % | 17.76 % | 12.48 % |
| 2026e | 68.35 % | 16.47 % | 11.93 % |
| 2025e | 68.35 % | 15.4 % | 11.22 % |
| 2024e | 68.35 % | 14.46 % | 11.28 % |
| 2023 | 68.35 % | 12.96 % | 12.16 % |
| 2022 | 61.72 % | 2.88 % | 0.35 % |
| 2021 | 68.45 % | 11.47 % | 1.53 % |
| 2020 | 64.39 % | 5.69 % | 0.75 % |
| 2019 | 65.06 % | 6.77 % | 1.57 % |
| 2018 | 65.66 % | 7.09 % | 0.59 % |
| 2017 | 59.77 % | -1.6 % | -5.78 % |
| 2016 | 57.52 % | -2.92 % | -7.87 % |
| 2015 | 50.51 % | -18.45 % | -27.85 % |
| 2014 | 54.95 % | -3.85 % | -22.27 % |
| 2013 | 45.49 % | -11.82 % | -18.21 % |
| 2012 | 43.66 % | -17.03 % | -24.55 % |
| 2011 | 43.8 % | -26.79 % | -30.07 % |
| 2010 | 45.05 % | -35.26 % | -63.09 % |
| 2009 | 27.73 % | -90 % | -109.55 % |
| 2008 | -12.74 % | -224.65 % | -262.6 % |
| 2007 | -92.54 % | -394.03 % | -399.25 % |
| 2006 | -324.32 % | -935.14 % | -978.38 % |
| 2005 | -1,500 % | -21,500 % | -21,600 % |
| 2004 | 68.35 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 68.35 % | 0 % | 0 % |
| 2005 | -1,500 % | -21,500 % | -21,600 % |
| 2006 | -324.32 % | -935.14 % | -978.38 % |
| 2007 | -92.54 % | -394.03 % | -399.25 % |
| 2008 | -12.74 % | -224.65 % | -262.6 % |
| 2009 | 27.73 % | -90 % | -109.55 % |
| 2010 | 45.05 % | -35.26 % | -63.09 % |
| 2011 | 43.8 % | -26.79 % | -30.07 % |
| 2012 | 43.66 % | -17.03 % | -24.55 % |
| 2013 | 45.49 % | -11.82 % | -18.21 % |
| 2014 | 54.95 % | -3.85 % | -22.27 % |
| 2015 | 50.51 % | -18.45 % | -27.85 % |
| 2016 | 57.52 % | -2.92 % | -7.87 % |
| 2017 | 59.77 % | -1.6 % | -5.78 % |
| 2018 | 65.66 % | 7.09 % | 0.59 % |
| 2019 | 65.06 % | 6.77 % | 1.57 % |
| 2020 | 64.39 % | 5.69 % | 0.75 % |
| 2021 | 68.45 % | 11.47 % | 1.53 % |
| 2022 | 61.72 % | 2.88 % | 0.35 % |
| 2023 | 68.35 % | 12.96 % | 12.16 % |
| 2024e | 68.35 % | 14.46 % | 11.28 % |
| 2025e | 68.35 % | 15.4 % | 11.22 % |
| 2026e | 68.35 % | 16.47 % | 11.93 % |
| 2027e | 68.35 % | 17.76 % | 12.48 % |
| 2028e | 68.35 % | 18.91 % | 12.35 % |
| 2029e | 68.35 % | 19.36 % | 15.34 % |
Insulet Aktienanalyse
What does Insulet do?
Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Insulet's Sales Figures
The sales figures of Insulet originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Insulet’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Insulet's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Insulet’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Insulet stock
How much was the turnover of the company Insulet compared to the previous year?
The revenue of Insulet has increased by 18.07% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Insulet?
The revenue of Insulet is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Insulet measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Insulet so important for investors?
The revenue of Insulet is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Insulet pay?
Over the past 12 months, Insulet paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insulet is expected to pay a dividend of 0 USD.
What is the dividend yield of Insulet?
The current dividend yield of Insulet is .
When does Insulet pay dividends?
Insulet pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Insulet?
Insulet paid dividends every year for the past 0 years.
What is the dividend of Insulet?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Insulet located?
Insulet is assigned to the 'Health' sector.
Wann musste ich die Aktien von Insulet kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Insulet from 1/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.
When did Insulet pay the last dividend?
The last dividend was paid out on 1/8/2025.
What was the dividend of Insulet in the year 2024?
In the year 2024, Insulet distributed 0 USD as dividends.
In which currency does Insulet pay out the dividend?
The dividends of Insulet are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Insulet stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Insulet
Our stock analysis for Insulet Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insulet Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
